Phaco-trabeculectomy with adjunctive intra-vitreal injection of bevacizumab (Avastin). A preliminary study

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-08000716

Enrollment

Unknown

Registered

2008-03-20

Start date

2008-03-25

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

1:Phaco-Trabeculectomy with intravitreal injection of Bevacizumab (Avastin) for 60 to 90 min

Eligibility

Sex/Gender

Male

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 years or above; 2. Eyes that undergo phaco-trabeculectomy; 3. Patient able and willing to give informed consent to phaco-trabeculectomy with intra-vitreal injection of bevacizumab.

Exclusion criteria

Exclusion criteria: 1. Single functional eye; 2. Pregnant patients; 3. Patients refusing phaco-trabeculectomy or bevacizumab injection; 4. Use of anticoagulants or anti-platelet therapy other than aspirin/NSAIDs within 14 days of surgery; 5. Presence of a non-healing wound, ulcer, fracture, or any medical condition associated with bleeding.

Design outcomes

Primary

Measure	Time frame
Intra-ocular pressure;	—

Secondary

Measure	Time frame
1. Bleb morphology (with photographic record) 2. Visual acuity 3. Number of IOP-lowering medications 4. Corneal clarity and corneal endothelial cell count (by specular microscopy) 5. Posterior capsular opacification 6. Progression in glaucomatous optic neuropathy and visual field loss 7. Any complications from surgery;	—

Countries

China

Contacts

Public ContactProf. Dennis SC Lam

dennislam_cu_res@cuhk.edu.hk+852 27623134

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026